Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?
HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead Delivery Science and Genome Editing Innovations
We Think CRISPR Therapeutics (NASDAQ:CRSP) Can Easily Afford To Drive Business Growth
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Truist Financial Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds?
7 Children Given Bluebird's Skysona Developed Blood Cancer: Study
Cathie Wood's ARK Sheds Robinhood Stock, Adds to Amazon and Coinbase
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRISPR Therapeutics Deserves Its Lofty Valuation Even With Conservative Forecasts
RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating
Cathie Wood Stocks (CRSP, SHOP, SQ) Could Actually Be Darn Good Picks
With 66% Ownership of the Shares, CRISPR Therapeutics AG (NASDAQ:CRSP) Is Heavily Dominated by Institutional Owners
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older
CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Have Endured a 59% Loss From Investing in the Stock Three Years Ago
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers